

The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective

Katia Iskandar, Christine Roques, Souheil Hallit, Rola Husni-Samaha, Natalia Dirani, Rana Rizk, Rachel Abdo, Yasmina Yared, Matta Matta, Inas Mostafa, et al.

► **To cite this version:**

Katia Iskandar, Christine Roques, Souheil Hallit, Rola Husni-Samaha, Natalia Dirani, et al.. The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective. BMC Infectious Diseases, BioMed Central, 2021, 21 (1), pp.404. 10.1186/s12879-021-06084-w . inserm-03313679

HAL Id: inserm-03313679

<https://www.hal.inserm.fr/inserm-03313679>

Submitted on 4 Aug 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

Open Access



The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective

Katia Iskandar^{1,2,3*} , Christine Roques^{4,5}, Souheil Hallit^{2,6}, Rola Husni-Samaha^{7,8}, Natalia Dirani⁹, Rana Rizk^{2,10}, Rachel Abdo^{2,11}, Yasmina Yared¹², Matta Matta¹³, Inas Mostafa¹⁴, Roula Matta³, Pascale Salameh^{2,3,11} and Laurent Molinier¹⁵

Abstract

Background: Our aim was to examine whether the length of stay, hospital charges and in-hospital mortality attributable to healthcare- and community-associated infections due to antimicrobial-resistant bacteria were higher compared with those due to susceptible bacteria in the Lebanese healthcare settings using different methodology of analysis from the payer perspective .

Methods: We performed a multi-centre prospective cohort study in ten hospitals across Lebanon. The sample size consisted of 1289 patients with documented healthcare-associated infection (HAI) or community-associated infection (CAI). We conducted three separate analysis to adjust for confounders and time-dependent bias: (1) Post-HAIs in which we included the excess LOS and hospital charges incurred after infection and (2) Matched cohort, in which we matched the patients based on propensity score estimates (3) The conventional method, in which we considered the entire hospital stay and allocated charges attributable to CAI. The linear regression models accounted for multiple confounders.

Results: HAIs and CAIs with resistant versus susceptible bacteria were associated with a significant excess length of hospital stay (2.69 days [95% CI, 1.5–3.9]; $p < 0.001$) and (2.2 days [95% CI, 1.2–3.3]; $p < 0.001$) and resulted in additional hospital charges (\$1807 [95% CI, 1046–2569]; $p < 0.001$) and (\$889 [95% CI, 378–1400]; $p = 0.001$) respectively. Compared with the post-HAIs analysis, the matched cohort method showed a reduction by 26 and 13% in hospital charges and LOS estimates respectively. Infections with resistant bacteria did not decrease the time to in-hospital mortality, for both healthcare- or community-associated infections. Resistant cases in the post-HAIs analysis showed a significantly higher risk of in-hospital mortality (odds ratio, 0.517 [95% CI, 0.327–0.820]; $p = 0.05$).

(Continued on next page)

* Correspondence: katia_iskandar@hotmail.com

¹Department of Mathématiques Informatique et Télécommunications, Université Toulouse III, Paul Sabatier, INSERM, UMR 1295, F-31000 Toulouse, France

²INSPECT-LB: Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban, Beirut, Lebanon

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Conclusion: This is the first nationwide study that quantifies the healthcare costs of antimicrobial resistance in Lebanon. For cases with HAIs, matched cohort analysis showed more conservative estimates compared with post-HAIs method. The differences in estimates highlight the need for a unified methodology to estimate the burden of antimicrobial resistance in order to accurately advise health policy makers and prioritize resources expenditure.

Keywords: Antimicrobial resistance, Healthcare cost, Length of stay, In-hospital mortality

Background

Antibiotics are known to generate a positive externality on society by preventing the spread of bacterial infections [1–4]. Since their discovery in the past century, the misuse and abuse of antibiotics [5–9] has led to the selection of resistant bacteria and generated extra costs that yielded to a negative societal externality by increasing the burden of bacterial illnesses and eroding the effectiveness of antibiotics for future cases [4–10]. In recent years, antibiotic resistance became a public health priority and triggered global actions. One Health initiatives [11–13] tried to address current related market failures and support measures to mitigate its detrimental worldwide impact [14, 15]. With the increased limitations in healthcare resources, expenditures on programs that reduce resistance must efficiently be allocated [2]. Accurate estimates of the economic burden of antimicrobial resistance (AMR) provide a baseline tool to study the cost-effectiveness of interventions to mitigate this global crisis and gives policymakers the incentives needed to invest in research and funding programs that track and prevent the spread of resistance [10–19]. Literature review in the field shows that health economics failed so far to demonstrate the real cost of resistance [10–20]. Published studies quantifying the economic burden of AMR reported a wide variability of cost estimates and showed heterogeneity of methodological assumptions [10, 18, 21–27]. The majority of data findings originate from high-income countries with unique Health Systems that limit the comparability of results with Low- and Middle-income countries (LMICs) and highlight the gap in research in these regions [28]. Lebanon is a middle-income country facing multiple challenges ranging from scarce financial resources, migrants and asylum seekers challenges, loose health system rules and regulations, economic and ecosystem issues, in addition to the fragmented health system and the diversity of health policy. In a country struggling for cost containment, the estimates of the economic and healthcare burden of AMR needed from multiple perspectives.

Research in the field has mainly focused on the epidemiology of selected pathogens and their virulence [29, 30] and the health impact of resistance [29, 31–50]. Current data on AMR originate from academic research

and the society of infectious diseases that both collaborate with different public and private hospitals [29, 30, 46]. The economic impact of AMR in Lebanon may be high compared with other middle-income countries due to the availability of antibiotics over-the-counter [29], the high incidence of AMR [29], the misuse and abuse of antibiotics in human health, animal health and the agricultural sector [51, 52]. Quantifying the burden of AMR in the healthcare settings is the only starting point to estimate the costs of resistance and provide high-quality estimates based on available recommendations from different systematic reviews, published literature, and experts in the field [10, 18, 20, 22, 27]. Here, we aimed to quantify the excess healthcare costs, length of stay, and in-hospital mortality associated with antimicrobial-susceptible versus -resistant infections from the payer perspective using a conventional method for studying the costs of community-associated-infections (CAIs) and two different methodologies of analysis previously adapted in the literature [53, 54] for estimating the costs of healthcare-associated-infections (HAIs) and compare attributable results.

Context

The republic of Lebanon is a democratic, parliamentary state, classified by the World Bank (2020) as an upper-middle income country [55]. It is located in the near east, at the crossroads of the three continents: Europe, Asia, and Africa. The long history of conflicts contributed to the economic downturn and fragile health system and to the development of non-governmental organizations (NGOs) and private institutions that became the major provider of health services as well as the main contractor to the Ministry of Public Health (MOPH) for the provision of healthcare [56]. The total number of hospitals in Lebanon is 165, among which the private sector accounts for the vast majority of 137 institutions mostly located in the capital region. Hospitals in Lebanon cover acute as well as long-term stays and offer all types of medical and surgical services. The vast majority of public institutions have less than 100 beds and autonomous governance while the total number of hospital beds is 2550 [56]. The private sector is the primary provider of healthcare services in Lebanon. The number of beds varies between 80 and 400 beds.

This sector is well equipped with highly trained staff and variable financial resources, offering superior multidisciplinary services. The private sector makes up a total of 12,648 hospital beds.

Methods

a. Study design

We performed a prospective multi-centre cross-sectional cohort study in tertiary acute-care centers across Lebanon from the payer perspective. We assumed that infections due to resistant- compared with –susceptible bacteria were the independent exposure of interest, and we evaluated their impact on excess LOS, excess hospital charges, and in-hospital mortality.

b. Settings

Hospitals were either teaching or non-teaching, from private or public sectors. We contacted hospital directors and Institutional Review Boards (IRB) to grant us access to the hospital financial, clinical, and microbiological database. Hospitals are enrolled based on the location and their willingness to share financial data. The majority were reluctant. Each hospital gave its ethical approval before proceeding to data collection. Patient consent is not obtained as data were collected and analyzed anonymously. The study started in January 2016 and ended in December 2017.

Exposures

We considered all documented patients exposures defined by the causative bacteria (gram-positive and gram-negative) and antimicrobial susceptibility testing due to either antibiotic-resistant or –susceptible isolates other than tuberculosis. We excluded (1) the probabilistic infections considered non-documented infections and (2) the cases of colonization defined by the Center of Diseases control and prevention (CDC) [100] as “the presence of microorganisms on skin, on mucous membranes, in open wounds, or in excretions or secretions but are not causing adverse clinical signs or symptoms”. We labeled non-susceptible and intermediate susceptibility as resistant. We considered high priority pathogens according to the definition of the World Health Organization (WHO) and the Centers for Disease Control (CDC), a primary priority of the study [6, 30, 57]. We defined antimicrobial acquired resistance as:

- *Enterobacteriaceae* resistant to carbapenems, fluoroquinolones, aminoglycosides, and third-generation cephalosporins
- *Acinetobacter baumannii* resistant to carbapenems
- *Pseudomonas aeruginosa* resistant to carbapenems
- *Enterococcus faecalis* and *Enterococcus faecium* resistant to vancomycin

- *Staphylococcus aureus* resistant to oxacillin
- *Streptococcus pneumoniae* resistant to penicillins, and *Streptococcus B* resistant to clindamycin

Data collection

We recruited five investigators, four on-site in addition to one research assistant, who were all trained on standardized data collection. We adapted the data collection sheet based on similar cohort studies [58–64] and the particularities of the Lebanese healthcare system. Covariates fell into the following three broad categories: (1) patient demographic characteristics at baseline, (2) factors present at admission, (3) factors arising during the hospitalization before the onset of infection, (4) antibiotic susceptibility testing results in addition to (5) the issued hospital charges per patient case (proforma). All events were adequately recorded, including time zero defined as the time of admission, in addition to the time to onset of infection, time of patient enrollment, and time of hospital discharge alive or dead [65–67].

c. Participants

We enrolled 1289 adult patients hospitalized for more than 48 h with either healthcare- or community-associated infection due to at least one antimicrobial-resistant bacteria or to all antimicrobial –susceptible bacteria (control group). The excluded cases were patients admitted to the ambulatory care unit, to a psychiatric unit, or other non-acute care units. We also excluded infections with *Mycobacterium sp.* Patients with an extended length of stay (LOS) post-infection that exceeded 45 days were not enrolled in the study because we consider based on local evidence that they may be attributable to other conditions like those related to underlying non-communicable diseases. Patients were diagnosed with either CAIs or HAIs associated with one or multiple bacteria. Resistant cases are those infected with at least one resistant bacteria documented by the results of antibiotic susceptibility testing. Patient were followed from the date of admission till discharge (i.e. alive or dead) from the hospital (Fig. 1).

d. Covariates

We considered as potential confounders the patient characteristics at baseline like patient age, gender, and patient comorbidity [68], and hospitalization(s) within the last 30 days. The dependent variables were excess LOS, excess hospital charges, and time to in-hospital mortality, all measured post-infection. The accurate recording of the date and time stamps made it possible to determine the time-varying factors arising before and after an infection like mechanical ventilation, insertion of a catheter, and stay in the intensive care unit. We did not account for events occurring post-infection to avoid

the control of intermediates in the causal pathway. We included the severity of illness represented by the acute physiological assessment and chronic health evaluation (APACHE) score [69] for descriptive purposes only since the timing of score determination was unknown. We accounted for the appropriateness of empirical antibiotic therapy (i.e. the administration of the antibiotics, after the time of specimen culture, to which specific isolate displayed in vitro susceptibility) to avoid the overestimation of the effect of AMR on patient outcomes.

e. Data sources and measurements

Microbiological method

We obtained the antimicrobial susceptibility testing results from the hospital laboratory and microbiology database. All laboratories adhered to current guidelines mainly from the Clinical and Laboratory Standards Institute (CLSI), in addition to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Antibiogram Committee of the French Microbiology Society (CA-SFM) [70, 71].

Cost estimation

The sources of costs are the hospital's financial database. Data included detailed total hospital stay charges, pharmacy expenditures, antibiotics charges, medical accessories, and serums, laboratory and pathology laboratory charges, imaging charges, Mechanical ventilation, third-party payer reimbursement, patient co-payment, and total hospitalization charges. All costs were expressed in Lebanese pounds and converted to US dollar currency (1US dollar =1507.5 Lebanese Lira L.L). Total hospitalization costs may include infection prevention and control costs that were not provided by the hospitals in detail. The cost of hospitalization per patient case is the product of the billed charges during the hospitalization.

Each case is assigned a number generated by the institutional database.

f. Outcomes of interest

The primary outcomes were to estimate the excess hospital charges, excess LOS, and in-hospital mortality in patients with CAIs and HAIs due to antibiotic-resistant compared with susceptible bacteria from the payer perspective and to compare the differences in the results for cases of HAIs between post-HAIs and matched cohorts analysis.

g. Statistical analysis

For data entry, we used the Statistical Package for Social Sciences (SPSS) version 23.0 software (SPSS Inc., Chicago, IL, USA). We conducted a separate analysis for community-associated infections and healthcare-

associated infections due to antibiotic-resistant versus -susceptible bacterial isolates. For CAIs, we used the conventional method and accounted for the LOS, hospital discharge, and in-hospital mortality for the entire hospital stay from admission to patient discharge from the hospital. We performed two different analyses for cases with HAIs and adjusted for the LOS, hospital charges, and mortality incurred post-infection: (1) Post-infection HAIs where we accounted in terms of hospital charges and LOS for the time from infection as defined by the date of the first culture till discharge from the hospital alive or dead and (2) matched analysis to minimize the risk of time-dependent bias where patients were matched at the analysis stage based on age, gender, Charlson comorbidity index, and on time to infection using the propensity score matching method. We undertook the two analyses to compare the resulting estimates and their effect on outcomes of interest. We also adjusted for the time-varying confounders before infection and accounted for the variable of the timing of infection to decrease the time-dependent bias.

Descriptive statistics

We used the student t-test for quantitative variables and the Chi-square test for qualitative variables. We summarized the continuous variables as median with interquartile (IQR), or as means with standard deviation (SD), and the ordinal variables as count with percentage.

Estimation of the excess LOS and excess hospital charges

We built linear regression models to identify the impact of independent variables on the excess LOS and excess hospital charges; the independent variable in all models was the infection with resistant bacteria. All regression models assumed a linear relationship between variables and outcomes of interest.

For patients with CAIs, we used the stepwise forward regression analysis procedure. We accounted for baseline characteristics and associated factors arising at admission. Independent variables in the model included age, gender, and comorbidity, in addition to previous exposure to antibiotics.

For HAIs, we build two separate models to compare the effect of independent variables on the outcomes of interest: (1) the Post-HAIs cohort and (2) the matched cohorts. To correct for time variation of some exposures, we included in the models the stay in the intensive care unit and the time to infection as the time-varying factors arising before infection, in addition to other independent variables listed in the CAIs analysis. Other variables like the severity of illness score and the insertion of a catheter were not adjusted for in the model because the timing of events was unknown.

Estimation of in-hospital mortality

We used cox proportional hazards models to investigate the association between infections due to antibiotic-resistant versus -susceptible bacteria and the risk of in-hospital mortality. We included the same variables used for the linear regression models above for CAIs and HAIs in addition to the appropriateness of empirical antibiotic therapy. We performed a stepwise analysis. We also built logistic regression models and accounted for the same variables previously included in cox regression using the stepwise analysis to test factors associated with in-hospital mortality in patients with resistant versus susceptible infections.

Results

The range of bacterial isolates associated with the community- and healthcare-infections are listed as high alerts by the World Health Organization (WHO) and the Center for Diseases Prevention and Control (CDC). The isolated bacteria highly encountered in cases of HAIs compared with CAIs are *Acinetobacter baumannii* carbapenem-resistant, *Pseudomonas aeruginosa* carbapenem-resistant, multidrug resistant (MDR) *Pseudomonas aeruginosa*, and *Methicillin-resistant Staphylococcus aureus* (MRSA). *Enterobacteriaceae* either *ESBL-producing* or carbapenem-resistant are nearly equally associated with CAIs and HAIs. (Table 1).

The baseline demographic characteristics of enrolled patient's show that multiple factors are associated with resistant cases either arising at baseline or during hospitalization. Prior exposure to antibiotics was the only common risk factor for developing either community- or -healthcare-associated infections due to resistant bacteria. A higher Charlson index score was a significant risk for developing CAIs with resistant bacteria. During hospitalization, clinical factors significantly associated with infections due to resistant cases included transfer to the ICU, insertion of a urinary catheter, mechanical ventilation, days of mechanical ventilation, and inappropriateness of antibiotic therapy. Not all listed clinical parameters exhibited significant results in the

matched cohort group. CAIs and HAIs associated with resistant bacteria were at a higher risk of all-cause mortality and an increase in the hospital charges estimates. The median LOS post-infection did not significantly differ in matched patients with resistant compared with susceptible cohorts in both groups (CAIs and post-HAIs). (Table 2).

The estimates of the excess length of stay and hospital charges are incurred post-infection per patient case either community-or healthcare-associated infections due to antibiotic-resistant compared with -susceptible bacteria. The linear regression shows that CAIs with resistant bacteria extend the length of hospital stay by a statistically significant estimate of (2.2 [95% CI, 1.2–3.3]; $p < 0.001$) days and result in an additional (\$889 [95% CI, 378–1400]; $p = 0.001$) excess hospital charges compared with susceptible cohorts. HAIs due to resistant bacteria showed a statistically significant higher excess hospital charges (\$1297 [95% CI, 627–1966]; $p < 0.001$) and longer excess LOS (2.1 days [95% CI, 0.9–3.2]; $p < 0.001$). Regression results in the matched cohort group showed more conservative estimates compared with the Post-infection HAIs group by a statistically significant lower difference of 31% in excess LOS and 14% excess hospital charges. Previous exposure to antibiotics and stay in the ICU were the independent variables associated with excess LOS in the post-HAI and matched cohort analysis. Results show that higher comorbidity index scores were associated with increased LOS in the CAIs and post-HAIs analysis compared with the matched cohort analysis. Independent variables in the model associated with excess hospital charges were advanced age, and the uses of antibiotics before admission in the post-HAI analysis, the high Charlson comorbidity index score, and ICU stay in the matched cohort analysis model. (Table 3).

The results of logistic regression that identifies factors associated with in-hospital mortality. The independent effect of infections with resistant bacteria on in-hospital mortality was significant in cohorts with HAIs (odds ratio, 0.517 [95% CI, 0.327–0.820]; $p = 0.05$). A higher

Table 1 Antibiotic-resistant bacteria associated with Community- and Healthcare associated infections

	Community-associated infection	Healthcare-associated infection
	<i>n</i>	<i>n</i>
Carbapenem-resistant <i>Acinetobacter baumannii</i>	8 (16%)	42 (84%)
Carbapenem-resistant <i>Pseudomonas aeruginosa</i>	7 (21%)	26 (79%)
Multidrug-resistant <i>Pseudomonas aeruginosa</i>	11 (34%)	21 (66%)
Carbapenem-resistant <i>Enterobacteriaceae</i>	10 (43%)	13 (56%)
<i>Enterobacteriaceae</i> , <i>ESBL-producing</i>	148 (45%)	181 (55%)
<i>Methicillin-resistant Staphylococcus aureus</i> (MRSA)	12 (35%)	22 (65%)
<i>Erythromycin-resistant group A streptococcus</i>	5 (71%)	2 (29%)

Data are displayed as number (%) of isolated bacteria

Table 2 Patient characteristics, clinical and economic outcomes

	Healthcare-associated infections						Community-associated infections		
	Post-HAI method			Matched Method			Conventional method		
	Resistant	Susceptible	p-values	Resistant	Susceptible	p-values	Resistant	Susceptible	p-values
No.	374	283		238	238		299	333	
Characteristics prior to infection									
Age (median [IQR])	69 (56–80)	67 (52–78)	0.174	67 (55–80)	68 (53–79)	1.000	81 (69–85)	70 (46–79)	0.152
Female sex	170 (45%)	135 (48%)	0.311	105 (44%)	117 (49%)	0.156	152 (51%)	191 (57%)	0.059
Previous hospitalization ^a	250 (67%)	182 (64%)	0.276	169 (71%)	147 (62%)	0.021	–	–	1.000
Transfer from another healthcare facility	22 (6%)	18 (6%)	0.462	15 (6%)	14 (6%)	0.500	–	–	
Invasive surgery	124 (33%)	80 (28%)	0.104	74 (31%)	73 (31%)	0.500	66 (22%)	60 (18%)	0.120
Charlson Co-morbidity Index (median [IQR])	4 (3–6)	4 (2–6)	0.205	4 (3–6)	4 (2–6)	0.854	6 (5–8)	5 (1–6)	0.002
Previous antibiotic exposure ^a	67 (18%)	35 (12%)	0.032	46 (19%)	32 (13%)	0.054	52 (17%)	36 (1%)	0.012
Infection and patient outcomes									
A-Clinical parameters									
ICU admission	124 (33%)	75 (26%)	0.040	70 (29%)	60 (25%)	0.177	66 (22%)	39 (12%)	< 0.001
ICU days (median [IQR])	9 (4–18)	6 (3–11)	0.144	8 (4–18)	6 (3–10)	0.237	8 (12–19)	6 (2–20)	0.987
Central venous catheter	60 (16%)	35 (12%)	0.112	35 (15%)	25 (10%)	0.107	27 (10%)	15 (36%)	0.017
Central venous catheter days (median [IQR])	11 (4–20)	8 (4–11)	0.164	12 (5–18)	7 (4–11)	0.076	11 (5–17)	6 (3–20)	0.894
Urinary catheter	143 (38%)	90 (32%)	0.052	82 (48%)	89 (37%)	0.283	85 (29%)	61 (18%)	0.004
Urinary catheter days (median [IQR])	8 (5–16)	8 (5–11)	0.385	7 (5–16)	8 (5–11)	0.644	12 (8–18)	6 (3.5–19.5)	0.943
Mechanical ventilation	86 (23%)	42 (15%)	0.005	48 (20%)	36 (15%)	0.093	29 (10%)	16 (5%)	0.013
Mechanical ventilation days (median [IQR])	9 (2.5–17)	0 (0–4)	< 0.001	7 (2–17)	0 (0–4)	0.001	11 (5–15)	1 (0–5)	0.002
Infection site									
Bloodstream	65 (56%)	51 (18%)	0.455	44 (18%)	39 (16%)	0.315	39 (13%)	44 (13%)	0.522
Urinary tract	213 (57%)	115 (41%)	< 0.001	134 (56%)	97 (41%)	< 0.001	197 (66%)	201 (60%)	0.053
Respiratory tract	92 (24%)	44 (15%)	0.003	41 (17%)	50 (21%)	0.176	27 (9%)	32 (10%)	0.456
Intraabdominal	16 (4%)	29 (10%)	0.002	12 (5%)	20 (8%)	0.100	17 (6%)	34 (10%)	0.025
Skin/Soft tissue/Osteomyelitis	88 (23%)	76 (27%)	0.188	63 (26%)	71 (30%)	0.238	60 (20%)	41 (12%)	0.002
Positive culture ≥ 2	88 (23%)	32 (11%)	< 0.001	59 (25%)	29 (12%)	< 0.001	51 (17%)	257%	< 0.001
Polymicrobial	74 (20%)	19 (7%)	< 0.001	54 (23%)	18 (8%)	< 0.001	44 (15%)	20 (6%)	< 0.001
APACHE score II (median [IQR])	6 (1–16)	1 (1–12)	0.527	4 (1–19)	1 (1–12)	0.706	–	–	
Appropriate antibiotic therapy	203 (54%)	248 (88%)	< 0.001	203 (85%)	203 (85%)	1.000	193 (64%)	287 (86%)	< 0.001
In-hospital Mortality	81 (72%)	32 (28%)	< 0.001	41 (61%)	26 (39%)	0.032	24 (65%)	13 (35%)	0.021
Mortality due to infection	49 (77%)	15 (23%)	0.135	25 (64%)	14 (36%)	0.373	11 (58%)	8 (42%)	0.286
B-Economic parameters									
LOS prior to index date (median [IQR]), days	0 (0–4)	0 (0–4)	0.426	0 (0–4)	0 (0–4)	0.520	–	–	
LOS post index date (median [IQR]), days	7 (4–14)	6 (3–10)	0.016	7 (5–14)	7 (4–11)	0.408	7 (4–12)	5 (3–8)	< 0.001
Stay charges at ward level ^b	761 (1094)	643 (797)	0.059	790 (1181)	661 (792)	0.200	534 (590)	364 (323)	< 0.001
ICU stay charges ^b	852 (2049)	508 (1252)	0.007	726 (1930)	466 (1158)	0.077	366 (1093)	240 (47)	0.109
Total stay charges ^b	1122	910 (1350)	0.063	1045	894 (1260)	0.220	851 (1151)	578 (822)	0.001

Table 2 Patient characteristics, clinical and economic outcomes (Continued)

	Healthcare-associated infections						Community-associated infections		
	Post-HAI method			Matched Method			Conventional method		
	(1532)			(1402)					
Pharmaceuticals charges^b	1872 (3137)	1129 (1680)	< 0.001	1851 (3458)	1030 (1505)	0.001	952 (1291)	628 (1191)	0.001
Antibiotics charges ^b	639 (1365)	314 (598)	< 0.001	609 (1475)	269 (426)	0.001	378 (649)	193 (366)	< 0.001
Medical Accessories charges^b	252 (1120)	163 (484)	0.243	231 (1176)	165 (461)	0.425	91 (288)	69 (450)	0.476
Oxygen charges^b	135 (658)	52 (151)	0.016	132 (760)	54 (151)	0.121	40 (168)	19 (73)	0.037
Imaging charges^b	310 (387)	292 (400)	0.224	318 (425)	277 (390)	0.280	252 (282)	185 (221)	0.001
Laboratory and microbiology charges^b	893 (1040)	756 (910)	0.018	868 (984)	714 (872)	0.071	638 (1080)	435 (413)	0.002
Third-party payment^b	3865 (4673)	2709 (3053)	< 0.001	3740 (4826)	2567 (2701)	0.001	2829 (3183)	1930 (2186)	< 0.001
Patient co-payment^b	379 (1684)	126 (764)	< 0.001	513 (1066)	341 (582)	0.030	263 (1217)	104 (492)	0.001
Total charges from index date^b	4363 (5052)	2800 (3221)	< 0.001	4278 (5027)	2882 (3108)	< 0.001	329 (601)	199 (321)	< 0.001

Data are displayed as mean (standard deviation) or number (%) of patients unless indicated otherwise

Percentages were rounded to the nearest whole number

Index date: date of first positive culture

a Within the preceding 90 days

b Hospital charges from index date till discharge expressed as mean (SD), USD

Community-associated infections were defined as those diagnosed within first 3 days of hospitalization in patients who had not been hospitalized in the previous 7 days. Healthcare-associated infections were defined as those diagnosed on third day in hospital or later

Abbreviations: n, sample size; IQR, interquartile range; SD, standard deviation; ICU, Intensive care unit; CV, Central venous; APACHE II, Acute Physiology and Chronic Health Evaluation; LOS, Length of stay; USD, United States dollars

Charlson comorbidity index score increased the odds of in-hospital mortality in all cohort groups. An increase in time to infection was an additional independent factor associated with in-hospital mortality due to HAIs in both the Post-HAIs and matched groups. Cox regression models explore the daily hazard of reaching the endpoint of discharge alive or in-hospital mortality in individuals with CAIs and HAIs.

The hazard ratio of infection with resistant bacteria did not appear to be significantly associated with an increased hazard of in-hospital mortality. (Table 4).

Discussion

Our study is the first in Lebanon to quantify nationwide the economic burden of hospitalized cases with CAIs or HAIs from the payer perspective. We compared

Table 3 Regression analyses of excess hospital charges and excess LOS attributable to antibiotic-resistant bacteria

	Unstandardized beta	95% Confidence Interval		R ²	p-value
		Upper	Lower		
Community-associated infection – Conventional method					
Excess LOS post-infection, days	2.2	1.2	3.3	0.027	< 0.001
Excess hospital charges, \$USD	889	378	1400	0.046	0.001
Healthcare-associated infection – “Post-infection HAI” method					
Excess LOS post-infection, days	2.1	0.9	3.2	0.140	< 0.001
Excess hospital charges, \$USD	1297	627	1966	0.274	< 0.001
Healthcare-associated infection – Matched method					
Excess LOS post-infection, days	1.6	0.3	2.9	0.135	0.016
Excess hospital charges, \$USD	1139	471	1807	0.229	0.001

Linear regression models were used assuming linear distribution. Unstandardized beta coefficient, excess LOS post-infection and excess hospital charges displayed in the table are those for the key independent variable: infection due at least one resistant bacteria. The other independent variables included in the community-associated infection regression model were patient age, gender, Charlson co-morbidity index and previous antibiotic exposure. In the healthcare-associated infection analyses, “post HAIs” analysis the other independent variables included in the regression models were patient age, gender, Charlson co-morbidity index, previous exposure to antibiotic, transfer to the ICU, insertion of central venous catheter, insertion of urinary catheter, mechanical ventilation, days of mechanical ventilation, time to infection, appropriateness of antibiotic therapy. p value < 0.05 is considered significant

Abbreviations: LOS, Length of stay; Coefficient, unstandardized Beta; CI, confidence interval; HAIs, healthcare –associated infections; ICU, intensive care unit

Table 4 Regression model – In-hospital Mortality

	<i>Odds ratio</i>	<i>95% Confidence Interval</i>		<i>p-value</i>
Community-associated infection				
Charlson comorbidity index	1.399	1.230	1.590	< 0.001
Healthcare-associated infection – “Post-infection HAIs” analysis				
At least one resistant bacteria	0.517	0.327	0.820	0.050
Charlson comorbidity index	1.144	1.038	1.261	0.007
Age	1.024	1.007	1.041	0.005
Time to infection	1.078	1.040	1.117	< 0.001
Healthcare-associated infection – Propensity score matching analysis				
Charlson comorbidity index	1.258	1.140	1.389	< 0.001
Time to infection	1.066	1.022	1.111	0.003

The dependent variable is death or discharge alive. The key dependent variable is CAIs or HAIs with at least one resistant bacteria. Other independent variables included in the community-associated infection regression model were patient age, gender and Charlson co-morbidity index. In the healthcare-associated infection models, “post HAIs” and matched cohorts, the other independent variables were patient age, gender, Charlson co-morbidity index, previous exposure to antibiotics, time to infection, transfer to the Intensive care unit, mechanical ventilation, insertion of a urinary catheter, insertion of a central venous catheter, appropriateness of antibiotic therapy

Abbreviations: CAIs, community-associated infections; HAIs, healthcare –associated infections

infections due to antimicrobial-resistant with -susceptible bacteria rather than with uninfected as a control group to avoid overestimation of the economic burden of resistance [23, 24, 72–75]. Although the payer perspective is considered narrow in scope, it allows to demonstrate the differences in outcomes estimates between resistant versus susceptible cases and offer baseline data for policymakers to evaluate the cost-effectiveness of current infection control and prevention practices to prevent AMR, in an era where the health system is struggling with scarce resources [10, 18, 27, 76].

The estimation of costs followed the bottom-up microcosting, considered a reliable method for identifying and valuing relevant cost components in the healthcare setting [17, 77]. The time and date stamp allowed to adjust for multiple confounders arising before the onset of infection and to avoid the allocation of intermediate mediators in the causal pathway [23, 27, 53, 78–80]. We only considered the severity of illness represented by the APACHE score in the descriptive analysis because the timing of the score estimation was unknown. Accounting for the severity of illness score is thought to accurately predict the clinical outcomes associated with resistance if the optimal time to estimate the severity of illness is 24 h before the first culture-positive specimen sample [23, 79–82]. We adjusted for the time-dependent bias by matching cohorts based on the day of infection [27, 67, 69].

We used the matched cohort with HAIs methodology at the study analysis stage according to age, gender, comorbidity, and timing of infection [23, 27, 53, 79, 83, 84]. The propensity score matching potentially reduces residual confounding compared with paired cohorts that control for a limited number of variables [10, 85]. A published study by Nelson and colleagues (2015) [53]

compared three methodologies of analysis: the conventional method, matched cohort analysis that accounted for the timing of infection, and the post-HAI method. Results showed more conservative estimates from the matched cohort analysis compared with the methodology based on post-infection data [53]. Our study showed a 26% reduction in excess hospital charges and a 13% decrease in excess LOS in the matched cohort analysis compared with the post-infection analysis.

Similar to a study by Neidell et al. [54], the comparison of LOS and costs due to resistant versus susceptible infections in healthcare settings showed significantly higher estimates associated with HAIs compared with CAIs. Healthcare- and community-associated infections due to susceptible versus resistant bacteria were associated with significantly higher median excess LOS (2.69 days versus 2.2 days) and mean excess hospital charges (\$1807 versus \$889). We used the survival analysis to estimate the hazard of in-hospital mortality attributable to resistant cases of infection. The results showed no significant increase in hazard ratio according to the three methods of analysis. The limited sample size associated with death cases during hospitalization and the lack of patient follow-up for at least 30 days post-discharge may potentially be contributory factors.

Systematic reviews in the field [10, 18, 23–27] showed a wide variability of estimates and heterogeneity of the methodology quantifying the burden of AMR. Failure to account for the HAIs as a time-varying exposure and to adjust for multiple confounders, competing risks, and for the time-varying confounders generate erroneous results [10, 18, 23, 27]. The multistate model is a recommended methodology of healthcare costs analysis associated with AMR [18, 27]. This method accounts for time-dependent bias and competing risks but do not

adjust for time-varying confounding [18, 27, 86]. The g-formulae may offer more reliable results by accounting for the time-varying confounders in addition to time-dependent bias and competing risks [10, 87, 88]. The g-formula estimates joint causal effects in the presence of a time-varying exposure and confounding. The g-formulae relies on assumptions that should be carefully determined to allow the robustness of the results [89]. Matching is a proposed method to avoid the time-dependent bias if the timing of infection was considered [21, 25]. Multiple studies used this method [55] and matched for patient characteristics like age, and gender or used diagnostic code, the severity of illness, and or the LOS before infection [10]. This reliability of these characteristics as an indicator of AMR infections is arguable not adequately tested [10, 85]. Each methodology of analysis and study design influences the quality of the studies despite that each has pitfalls and limitations [10, 18, 27, 87, 90] Jit et al. 2019 [10] proposed a conceptual framework for quantifying the economic burden of AMR and postulated that obtaining accurate estimates requires rigor and innovation in using the existing methodologies.

A standardized method for study design and analysis is highly needed. This method must take into consideration cross-borders differences and limitations to allow comparability and generalizability of results. Quantifying the burden of resistance may influence the fight against AMR if it provides evidence-based estimates [10, 18, 23, 27]. The global economic downturn has a profound impact on population health and the sustainability of healthcare systems leading to multiple cuts on the budget in both the public and private sectors [91]. Re-allocation of resources and health policy rely on quality data to orientate health expenditures. Data findings may allow us to examine the cost-effectiveness of current practices undertaken to mitigate resistance and orientate for the efficient prioritization of resource allocation to enhance global health [10]. The healthcare costs represent part of the burden of AMR to society. The opportunity cost associated with resistance shows what is missing due to resistance to enhance the welfare of the community if the payer is a public entity or to improve coverage of other diseases if the payer is a private entity. In Lebanon, implemented health policy to tackle AMR needs to strengthen the population-based surveillance on AMR consider the pre-requisite to study the economic burden of resistance [21] and expand to cover not only the human health but also the animal health and agriculture sector interfaces.

The limitations of the study are the factors that may affect the accuracy of the data. Our study included a wide range of infections due to different gram-positive

and gram-negative bacteria. Targeting either CAI or HAI type due to an antimicrobial-resistant compared with the same -susceptible species can generate more reliable estimates attributable to the associated outcomes. The same remark applied when targeting one specific mechanism of acquired resistance like carbapenemase production. The methodology of antimicrobial susceptibility testing is another concern due to the lack of standardization throughout the enrolled hospitals or at least no homogeneous methods and breakpoints taken into account to define the resistance. For cost estimation, we followed the bottom-up microcosting from the payer perspective in terms of hospital charges that may vary depending on the health system coverage and third-party contracts. For further accuracy, studies taking into account these limitations are recommended to confirm our findings: the standardization of study design and analysis methodology would allow the comparability and generalizability of results for a more informed national and global action to fight AMR.

Conclusion

Our study is the first nationwide study that quantifies the economic burden of antimicrobial resistance (AMR) in Lebanese hospitals, in comparison with sensitive bacteria. Matched cohort analysis showed more conservative estimates in cases of HAIs. The differences in estimates highlight the need for a unified methodology to estimate the burden of AMR and accurately advise health policymakers and prioritize resource expenditure on infection prevention and control programs.

Abbreviations

AMR: Antimicrobial resistance; APACHE: Acute physiological assessment and chronic health evaluation; CA-SFM: Antibiogram Committee of the French Microbiology Society; CAIs: Community-associated infections; CDC: Center of Diseases control and prevention; CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; HAIs: Healthcare-associated infections; IRB: Institutional Review Boards; IQR: Interquartile; LMICs: Low- and Middle-income countries; LOS: Length of stay; MDR: Multi-drug resistant; MOPH: Ministry of Public Health; NGOs: Non-governmental organizations; SD: Standard deviation; SPSS: Statistical Package for Social Sciences; WHO: World Health Organization

Acknowledgments

We would like to thank each and every person who gave us time and support and granted us access to clinical and economic data in all 10 hospitals throughout Lebanon. We highly value the trust of the hospital management and Institutional board review members and we thank all the colleagues and staff working in the infection disease department, pharmacy department, laboratory department, accounting department and quality department in the following hospitals: Lebanese Canadian Hospital, Horch Tabet; Middle East Institute of Health University Hospital, Mount Lebanon; Geitaoui Hospital, Beirut; Rafic Hariri University hospital, Beirut; Mounla Hospital, Tripoli, North Lebanon; Dar El Amal University Hospital, Baalbeck; American University Medical center, Rizk hospital, Beirut; Haroun Hospital, Mount Lebanon; Nabatieh Governmental hospital, Nabatieh, South Lebanon; Centre hospitalier du Nord, Zgharta, North Lebanon.

Authors' contributions

K.I. contributed to the formulation and evolution of overarching research goals and search strategy; L.M., P.S., C.R. supervised and coordinated the research activity planning and execution. K.I. wrote the manuscript; R.R., R.A., Y.Y., R.H., N.D., S.H., I.M., M.M., and R.M. contributed to the conception of the study and content editing. All authors read the manuscript, critically revised it for intellectual content and approved the final version.

Funding

Not applicable.

Availability of data and materials

The datasets generated and analyzed during the current study are available in the INSPECT-LB repository, <https://inspect-lb.org/data-repository/>

Declarations**Ethics approval and consent to participate**

The mentioned ethics committees approved the study and a written consent was obtained from the participants.

Rafic Hariri University Hospital, IRB approval Ref:INV-2016-302.

Lebanese American University, IRB approval Ref.LAUMCRH.RH.2.3/Feb/2015.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Mathématiques Informatique et Télécommunications, Université Toulouse III, Paul Sabatier, INSERM, UMR 1295, F-31000 Toulouse, France. ²INSPECT-LB: Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban, Beirut, Lebanon. ³Department of Pharmacy, Lebanese University, Mount Lebanon, Beirut, Lebanon. ⁴Department of Bioprocédés et Systèmes Microbiens, Laboratoire de Génie Chimique, Université Paul Sabatier Toulouse III, UMR 5503, Toulouse, France. ⁵Department of Bactériologie-Hygiène, Centre Hospitalier Universitaire, Toulouse, Hôpital Purpan, Toulouse, France. ⁶Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon. ⁷Department of Medicine, Lebanese American University, Byblos, Lebanon. ⁸Department of Infection Control, Lebanese American University Medical Center, Beirut, Lebanon. ⁹Department of Infectious Diseases, Dar El Amal University Hospital, Baalbeck, Lebanon. ¹⁰Department of Health Services Research, School CAPHRI, Care and Public Health Research Institute, Maastricht University, 6200, MD, Maastricht, The Netherlands. ¹¹Medical School, University of Nicosia, Nicosia, Cyprus. ¹²Department of Clinical Pharmacy, Geitaoui Hospital, Beirut, Lebanon. ¹³Department of Medicine, St Joseph University, Beirut, Lebanon. ¹⁴Department of Quality and Safety, Nabatieh Governmental Hospital, Nabatieh, Lebanon. ¹⁵Department of Medical Information, Centre Hospitalier Universitaire, INSERM, UMR 1027, Université Paul Sabatier Toulouse III, F-31000 Toulouse, France.

Received: 8 December 2020 Accepted: 16 April 2021

Published online: 01 May 2021

References

- Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. World Health Organization. Regional Office for Europe; 2010.
- Leal JR, Conly J, Henderson EA, Manns BJ. How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations. *Antimicrob Resist Infect Control*. 2017;6(1):53. <https://doi.org/10.1186/s13756-017-0211-2>.
- Burroughs T, Najafi M, Lemon SM, Knobler SL. The resistance phenomenon in microbes and infectious disease vectors: implications for human health and strategies for containment: workshop summary. National Academies Press; 2003.
- Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. *Soc Sci Med*. 1998;46(1):29–38. [https://doi.org/10.016/S0277-9536\(97\)00132-9](https://doi.org/10.016/S0277-9536(97)00132-9).
- World Health Organization. The evolving threat of antimicrobial resistance: options for action. World Health Organization; 2012.
- Control CD. Prevention. *Antibiotic resistance threats in the United States*, 2013. Centres for Disease Control and Prevention, US Department of Health and; 2013.
- Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet*. 2016;387(10014):176–87. [https://doi.org/10.1016/S0140-6736\(15\)00473-0](https://doi.org/10.1016/S0140-6736(15)00473-0).
- Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013;13(12):1057–98. [https://doi.org/10.1016/S1473-3099\(13\)70318-9](https://doi.org/10.1016/S1473-3099(13)70318-9).
- European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe 2012. Available from: <http://ecdc.europa.eu/en/publications/Publications/antimicrobialconsumption-europe-esac-net-2012.pdf>. 2014.
- Jit M, Ng DHL, Luangasanatip N, et al. Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. *BMC Med*. 2020;18(1):1–14.
- Cabrera-Pardo JR, Lood R, Udekwe K, Gonzalez-Rocha G, Munita JM, Järhult JD, et al. A one health—one world initiative to control antibiotic resistance: a Chile–Sweden collaboration. *One Health*. 2019;8:100100. <https://doi.org/10.1016/j.onehlt.2019.100100>.
- White A, Hughes JM. Critical importance of a one health approach to antimicrobial resistance. *EcoHealth*. 2019;16(3):404–9. <https://doi.org/10.1007/s10393-019-01415-5>.
- Solomon S. The unique contribution of one health to combating antibiotic resistance. *AMR control*. Retrieved from <http://resistancecontrol.info/2017/2017>.
- Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of antibiotic resistance transmission in low-and middle-income countries from a "one health" perspective—a review. *Antibiotics*. 2020;9(7):372. <https://doi.org/10.3390/antibiotics9070372>.
- Nadimpalli M, Delarocque-Astagneau E, Love DC, Price LB, Huynh BT, Collard JM, et al. Combating global antibiotic resistance: emerging one health concerns in lower-and middle-income countries. *Clin Infect Dis*. 2018; 66(6):963–9. <https://doi.org/10.1093/cid/cix879>.
- Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? *Health Econ*. 1996;5(3):217–26. [https://doi.org/10.1002/\(SICI\)1099-1050\(199605\)5:3<217::AID-HEC200>3.0.CO;2-S](https://doi.org/10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S).
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015.
- Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. *Antimicrob Resist Infect Control*. 2018;7(1):58. <https://doi.org/10.1186/s13756-018-0336-y>.
- Roope LS, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, Butler CC, San Tan P, Walker AS, Robotham JV, Wordsworth S. The challenge of antimicrobial resistance: what economics can contribute. *Science*. 2019; 364(6435).
- Smith R, Coast J. The true cost of antimicrobial resistance. *Bmj*. 2013;346(3): f1493. <https://doi.org/10.1136/bmj.f1493>.
- de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? *PLoS Med*. 2016;13(11):e1002184. <https://doi.org/10.1371/journal.pmed.1002184>.
- Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. *PLoS One*. 2017;12(12):e0189621. <https://doi.org/10.1371/journal.pone.0189621>.
- Gandra S, Barter D, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? *Clin Microbiol Infect*. 2014;20(10): 973–80. <https://doi.org/10.1111/1469-0691.12798>.
- Larson E. Factors associated with variation in estimates of the cost of resistant infections. *Med Care*. 2010;48(9):767.
- Smith R, Coast J. The economic burden of antimicrobial resistance: why it is more serious than current studies suggest; 2012.
- Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. *J Health Serv Res Policy*. 2002;7(2):111–7. <https://doi.org/10.1258/1355819021927764>.

27. Wozniak TM, Barnsbee L, Lee XJ, Pacella RE. Using the best available data to estimate the cost of antimicrobial resistance: a systematic review. *Antimicrobial Resist Infect Control*. 2019;8(1):26. <https://doi.org/10.1186/s13756-019-0472-z>.
28. Organization WH. Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization;2014.
29. Salameh P, Sacre H, Hallit S, Hajj A. Antibiotic resistance in Lebanon; 2018.
30. Shrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. *J Med Soc*. 2018;32(1):76. https://doi.org/10.4103/jms.jms_25_17.
31. Al Atrouni A, Hamze M, Jisr T, et al. Wide spread of OXA-23-producing carbapenem-resistant *Acinetobacter baumannii* belonging to clonal complex II in different hospitals in Lebanon. *Int J Infect Dis*. 2016;52:29–36. <https://doi.org/10.1016/j.ijid.2016.09.017>.
32. Baroud á, Dandache I, Araj G, et al. Underlying mechanisms of carbapenem resistance in extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates at a tertiary care Centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. *Int J Antimicrob Agents*. 2013;41(1):75–9. <https://doi.org/10.1016/j.ijantimicag.2012.08.010>.
33. Daoud Z, Hobeika E, Choucair A, Rohban R. Isolation of the first metallo- β -lactamase producing *Klebsiella pneumoniae* in Lebanon. *Rev Esp Quimioter*. 2008;21(2):123–6.
34. El-Najjar N, Farah M, Hashwa F, Tokajian S. Antibiotic resistance patterns and sequencing of class I integron from uropathogenic *Escherichia coli* in Lebanon. *Lett Appl Microbiol*. 2010;51(4):456–61. <https://doi.org/10.1111/j.1472-765X.2010.02926.x>.
35. Hammoudi D, Moubareck CA, Kanso A, Nordmann P, Sarkis DK. Surveillance of carbapenem non-susceptible gram negative strains and characterization of carbapenemases of classes a, B and D in a Lebanese hospital. *Lebanese Med J*. 2015;103(1973):1–8.
36. Hammoudi Halat D, Moubareck CA, Sarkis DK. Heterogeneity of carbapenem resistance mechanisms among gram-negative pathogens in Lebanon: results of the first cross-sectional countrywide study. *Microb Drug Resist*. 2017;23(6):733–43. <https://doi.org/10.1089/mdr.2016.0077>.
37. Moghnieh R, Araj GF, Awad L, Daoud Z, Mokhbat JE, Jisr T, et al. A compilation of antimicrobial susceptibility data from a network of 13 Lebanese hospitals reflecting the national situation during 2015–2016. *Antimicrobial Resist Infect Control*. 2019;8(1):41. <https://doi.org/10.1186/s13756-019-0487-5>.
38. Moghnieh R, Estaitieh N, Mugharbil A, et al. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. *Front Cell Infect Microbiol*. 2015;5:11.
39. Moghnieh R, Siblani L, Ghabdan D, el Mchad H, Zeineddine R, Abdallah D, et al. Extensively drug-resistant *Acinetobacter baumannii* in a Lebanese intensive care unit: risk factors for acquisition and determination of a colonization score. *J Hosp Infect*. 2016;92(1):47–53. <https://doi.org/10.1016/j.jhin.2015.10.007>.
40. Moghnieh RA, Musharrafieh UM, Husni RN, et al. *E. coli*, *K. pneumoniae* and *K. oxytoca* community-acquired infections susceptibility to cephalosporins and other antimicrobials in Lebanon. *Lebanese Med J*. 2014;103(1151):1–6.
41. Tokajian S, Haddad D, Andraos R, Hashwa F, Araj G. Toxins and antibiotic resistance in *Staphylococcus aureus* isolated from a major hospital in Lebanon. *ISRN Microbiol*. 2011;2011:1–9. <https://doi.org/10.5402/2011/812049>.
42. Araj GF, Avedissian AZ, Itani LY, Obeid JA. Antimicrobial agents active against carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates in Lebanon. *J Infect Develop Countries*. 2018;12(03):164–70. <https://doi.org/10.3855/jidc.9729>.
43. Bahnan W, Hashwa F, Araj G, Tokajian S. Emm typing, antibiotic resistance and PFGE analysis of *Streptococcus pyogenes* in Lebanon. *J Med Microbiol*. 2011;60(1):98–101. <https://doi.org/10.1099/jmm.0.023317-0>.
44. Chamoun K, Farah M, Araj G, Daoud Z, Moghnieh R, Salameh P, et al. Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data. *Int J Infect Dis*. 2016;46:64–70. <https://doi.org/10.1016/j.ijid.2016.03.010>.
45. El-Herte RI, Kanj SS, Matar GM, Araj GF. The threat of carbapenem-resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology. *J Infect Public Health*. 2012;5(3):233–43. <https://doi.org/10.1016/j.jiph.2012.02.003>.
46. Matar G, Cuzon G, Araj G, et al. Oxacillinase-mediated resistance to carbapenems in *Klebsiella pneumoniae* from Lebanon. *Clin Microbiol Infect*. 2008;14(9):887–8. <https://doi.org/10.1111/j.1469-0691.2008.02059.x>.
47. Matar G, Dandache I, Carrèr A, et al. Spread of OXA-48-mediated resistance to carbapenems in Lebanese *Klebsiella pneumoniae* and *Escherichia coli* that produce extended spectrum β -lactamase. *Ann Trop Med Parasitol*. 2010;104(3):271–4. <https://doi.org/10.1179/136485910X12647085215651>.
48. Matta R, Hallit S, Hallit R, Bawab W, Rogues A-M, Salameh P. Epidemiology and microbiological profile comparison between community and hospital acquired infections: a multicenter retrospective study in Lebanon. *J Infect Public Health*. 2018;11(3):405–11. <https://doi.org/10.1016/j.jiph.2017.09.005>.
49. Salem SE, Dahdouh E, Daoud Z. Resistance of gram-negative bacilli in Lebanon. *International Scholarly Research Notices*. 2013;2013.
50. Sfeir M, Obeid Y, Eid C, Saliby M, Farra A, Farhat H, et al. Prevalence of *Staphylococcus aureus* methicillin-sensitive and methicillin-resistant nasal and pharyngeal colonization in outpatients in Lebanon. *Am J Infect Control*. 2014;42(2):160–3. <https://doi.org/10.1016/j.ajic.2013.08.008>.
51. Jammoul A, El Darra N. Evaluation of antibiotics residues in chicken meat samples in Lebanon. *Antibiotics*. 2019 Jun;8(2):69. <https://doi.org/10.3390/antibiotics8020069>.
52. Zeina K, Fawwak S. Quantification of antibiotic residues and determination of antimicrobial resistance profiles of microorganisms isolated from bovine milk in Lebanon. *Food Nutr Sci*. 2013;4(07):1–9. <https://doi.org/10.4236/fns.2013.47A001>.
53. Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al. Reducing time-dependent Bias in estimates of the attributable cost of health care—associated methicillin-resistant *Staphylococcus aureus* infections. *Med Care*. 2015;53(9):827–34. <https://doi.org/10.1097/MLR.0000000000000403>.
54. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. *Clin Infect Dis*. 2012;55(6):807–15. <https://doi.org/10.1093/cid/cis552>.
55. World Bank. Country and lending groups 2020. 2020.
56. World Health Organization. (2010). *Country cooperation strategy for WHO and Lebanon: 2010–2015* (no. Who-EM/ARD/035/e). World Health Organization. Regional Office for the Eastern Mediterranean.
57. Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization. 2017;27:318–27.
58. Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant *Pseudomonas aeruginosa* acquisition. *BMC Health Serv Res*. 2012;12(1):122. <https://doi.org/10.1186/1472-6963-12-122>.
59. Cheah A, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. *Clin Microbiol Infect*. 2013;19(4):E181–9. <https://doi.org/10.1111/1469-0691.12132>.
60. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β -lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. *J Hosp Med*. 2014;9(4):232–8. <https://doi.org/10.1002/jhm.2157>.
61. Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and *Staphylococcus aureus* in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. *Eurosurveillance*. 2016;21(33):30319.
62. Stewardson AJ, Fankhauser-Rodriguez CM, De Angelis G, et al. Burden of bloodstream infection caused by extended-spectrum β -lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University hospital and a nationwide predictive model. *Infect Control Hosp Epidemiol*. 2013;34(2):133–43. <https://doi.org/10.1086/669086>.
63. Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum β -lactamase production in cases of *Escherichia coli* bloodstream infection. *J Glob Antimicrob Resist*. 2014; 2(2):107–9. <https://doi.org/10.1016/j.jgar.2014.01.005>.
64. Esteve-Palau E, Solande G, Sánchez F, Sorlí L, Montero M, Güerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing *Escherichia coli* requiring hospitalization: a matched cohort study. *J Infect*. 2015;71(6):667–74. <https://doi.org/10.1016/j.jinf.2015.08.012>.
65. Schumacher M, Allignol A, Beyersmann J, Binder N, Wolkewitz M. Hospital-acquired infections—appropriate statistical treatment is urgently needed! *Int J Epidemiol*. 2013;42(5):1502–8. <https://doi.org/10.1093/ije/dyt111>.
66. Barnett AG, Beyersmann J, Allignol A, Rosenthal VD, Graves N, Wolkewitz M. The time-dependent bias and its effect on extra length of stay due to

- nosocomial infection. *Value Health*. 2011;14(2):381–6. <https://doi.org/10.1016/j.jval.2010.09.008>.
67. Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. *J Clin Epidemiol*. 2012;65(11):1171–80. <https://doi.org/10.1016/j.jclinepi.2012.04.008>.
 68. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Clin Epidemiol*. 1987;40(5):373–83.
 69. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med*. 1985;13(10):818–29. <https://doi.org/10.1097/00003246-198510000-00009>.
 70. Wayne P. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing; 2011.
 71. Jehl F, Cattoen C. Comité de l'antibiogramme de la société française de microbiologie. *Recommandations* 2016. V1. 0 Février. 2016. p 117.
 72. Eliopoulos GM, Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. *Clin Infect Dis*. 2003;36(11):1433–7. <https://doi.org/10.1086/375081>.
 73. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. *Expert Rev Anti-Infect Ther*. 2008;6(5):751–63. <https://doi.org/10.1586/14787210.6.5.751>.
 74. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. *Value Health*. 2013;16(2):231–50. <https://doi.org/10.1016/j.jval.2013.02.002>.
 75. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. *Emerg Infect Dis*. 2004;10(6):1125–8. <https://doi.org/10.3201/eid1006.020665>.
 76. Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p's and q's. *Clin Infect Dis*. 2010;50(7):1017–21. <https://doi.org/10.1086/651110>.
 77. Tan SS, Rutten F, Van Ineveld B, Redekop W, Hakkaart-van RL. Comparing methodologies for the cost estimation of hospital services. *Eur J Health Econ*. 2009;10(1):39–45. <https://doi.org/10.1007/s10198-008-0101-x>.
 78. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β -lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. *J Antimicrob Chemother*. 2012;67(6):1311–20. <https://doi.org/10.1093/jac/dks065>.
 79. Thom KA, Shardell MD, Osih RB, Schweizer ML, Furuno JP, Perencevich EN, et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. *Infect Control Hosp Epidemiol*. 2008;29(11):1048–53. <https://doi.org/10.1086/591453>.
 80. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. *Epidemiology*. 2003;14(3):300–6. <https://doi.org/10.1097/01.EDE.0000042804.12056.6C>.
 81. VijayGanapathy S, Karthikeyan VS, Sreenivas J, Mallya A, Keshavamurthy R. Validation of APACHE II scoring system at 24 hours after admission as a prognostic tool in urosepsis: a prospective observational study. *Investigative Clin Urol*. 2017;58(6):453–9. <https://doi.org/10.4111/icu.2017.58.6.453>.
 82. Blot S, De Bacquer D, Hoste E, et al. Influence of matching for exposure time on estimates of attributable mortality caused by nosocomial bacteremia in critically ill patients. *Infect Control Hosp Epidemiol*. 2005;26(4):352–6. <https://doi.org/10.1086/502551>.
 83. Campbell RS, Emons MF, Mardekian J, Girgenti D, Gaffney M, Yu H. Adverse clinical outcomes and resource utilization associated with methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* infections after elective surgery. *Surg Infect*. 2015;16(5):543–52. <https://doi.org/10.1089/sur.2013.250>.
 84. Touat M, Opatowski M, Brun-Buisson C, Cosker K, Guillemot D, Salomon J, et al. A payer perspective of the hospital inpatient additional care costs of antimicrobial resistance in France: a matched case-control study. *Appl Health Econ Health Policy*. 2019;17(3):381–9. <https://doi.org/10.1007/s40258-018-0451-1>.
 85. Howard D, Cordell R, McGowan JE Jr, Packard RM, R Douglas Scott I, Solomon SL. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory workshop. *Clin Infect Dis*. 2001;33(9):1573–8. <https://doi.org/10.1086/323758>.
 86. Lee XJ, Stewardson AJ, Worth LJ, Graves N, Wozniak TM. Attributable length of stay, mortality risk and costs of bacterial healthcare-associated infections in Australia: a retrospective case-cohort study. 2020.
 87. Pouwels K, Vansteelandt S, Batra R, Edgeworth J, Smieszek T, Robotham J. Intensive care unit (ICU)-acquired bacteraemia and ICU mortality and discharge: addressing time-varying confounding using appropriate methodology. *J Hosp Infect*. 2018;99(1):42–7. <https://doi.org/10.1016/j.jhin.2017.11.011>.
 88. Wolkewitz M, Schumacher M, Rücker G, Harbarth S, Beyersmann J. Estimands to quantify prolonged hospital stay associated with nosocomial infections. *BMC Med Res Methodol*. 2019;19(1):111. <https://doi.org/10.1186/s12874-019-0752-6>.
 89. Keil AP, Edwards JK, Richardson DR, Naimi AI, Cole SR. The parametric G-formula for time-to-event data: towards intuition with a worked example. *Epidemiology* (Cambridge, Mass). 2014;25(6):889.
 90. Pouwels KB, Vansteelandt S, Batra R, Edgeworth J, Wordsworth S, Robotham JV. Estimating the Effect of Healthcare-Associated Infections on Excess Length of Hospital Stay Using Inverse Probability-Weighted Survival Curves. *Clin Infect Dis*. 2020;71(9):e415–20.
 91. Golinelli D, Toscano F, Bucci A, Lenzi J, Fantini MP, Nante N, et al. Health expenditure and all-cause mortality in the 'Galaxy' of Italian regional healthcare systems: a 15-year panel data analysis. *Appl Health Econ Health Policy*. 2017;15(6):773–83. <https://doi.org/10.1007/s40258-017-0342-x>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

